Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial results
Abstract
Background: Valoctocogene roxaparvovec, a gene therapy for severe hemophilia A, enables endogenous factor VIII (FVIII) expression and confers bleed control. Objectives: To present the final 5-year efficacy and safety results from the phase 3 GENEr8-1 trial. Methods: Adult men (N = 134) with severe hemophilia A without inhibitors who were using FVIII prophylaxis received one 6 × 1013 vg/kg infusion of valoctocogene roxaparvovec. End points included annualized bleeding rate (ABR), FVIII infusion rate, FVIII activity, Haemophilia-Specific Quality of Life Questionnaire for Adults, adverse events, and immunosuppressant use. Results: Median follow-up was 261.1 weeks; 128 of 134 participants completed the study. For the 112 participants who enrolled from a previous noninterventional study (rollover population), mean ABR for treated bleeds declined by 83.3% (P < .0001), mean FVIII infusion rate declined by 94.9% (P < .0001), and mean ABR for all bleeds declined by 78.1% in the 5-year efficacy evaluation period vs baseline. In 132 modified intention-to-treat participants, mean and median FVIII activity at week 260 was 13.7 and 6.2 IU/dL, respectively (chromogenic assay). In year 5, 77.8% of rollover participants had 0 treated bleeds. One participant resumed prophylaxis since the 4-year data cutoff (25/134 across all follow-up). Haemophilia-Specific Quality of Life Questionnaire for Adults total score was improved from baseline at year 5. In year 5, alanine aminotransferase elevations occurred in 51 of 129 participants who entered year 5. Immunosuppressants were not used to manage them. No serious treatment-related adverse events occurred after year 1. Conclusion: Valoctocogene roxaparvovec provides durable hemostatic efficacy, FVIII activity, and improved health-related quality of life for ≥5 years, with no new safety signals.
Related
- Evaluating Costs and Efficacy of rFVIII Prophylaxis Using Matching-Adjusted Indirect Comparisons in Hemophilia A
- Durability and diversity of human upper airway T cell memory
- Antigen avidity potentiates the durability of the vaccine immune response
- Modeling DDAVP response from endothelial storage to individualized dosing in mild hemophilia A and symptomatic carriers
- [Acquired hemophilia A associated with bullous pemphigoid and multiple myeloma: a case report].
BibTeX
@article{leavitt2026durability,
title = {{Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial results}},
author = {Andrew Leavitt and Johnny Mahlangu and Priyanka Raheja and Emily Symington and Doris Quon and Adam Giermasz and Gili Kenet and Gillian Lowe and Nigel Key and Carolyn Millar and Steven Pipe and Sheng-Chieh Chou and Robert Klamroth and Jane Mason and Hervé Chambost and Hervé Chambost and Flora Peyvandi and Elaine Majerus and Dominic Pepperell and Chee Wee Tan and Hua Yu and Konstantia-Maria Chavele and Margareth Ozelo},
journal = {Research and Practice in Thrombosis and Haemostasis},
year = {2026},
month = aug,
doi = {10.1016/j.rpth.2026.103416},
url = {https://hal.inrae.fr/hal-05723425v1},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial results
AU - Andrew Leavitt
AU - Johnny Mahlangu
AU - Priyanka Raheja
AU - Emily Symington
AU - Doris Quon
AU - Adam Giermasz
AU - Gili Kenet
AU - Gillian Lowe
AU - Nigel Key
AU - Carolyn Millar
AU - Steven Pipe
AU - Sheng-Chieh Chou
AU - Robert Klamroth
AU - Jane Mason
AU - Hervé Chambost
AU - Hervé Chambost
AU - Flora Peyvandi
AU - Elaine Majerus
AU - Dominic Pepperell
AU - Chee Wee Tan
AU - Hua Yu
AU - Konstantia-Maria Chavele
AU - Margareth Ozelo
PY - 2026
DA - 2026/08/31
JO - Research and Practice in Thrombosis and Haemostasis
DO - 10.1016/j.rpth.2026.103416
UR - https://hal.inrae.fr/hal-05723425v1
AB - Background: Valoctocogene roxaparvovec, a gene therapy for severe hemophilia A, enables endogenous factor VIII (FVIII) expression and confers bleed control. Objectives: To present the final 5-year efficacy and safety results from the phase 3 GENEr8-1 trial. Methods: Adult men (N = 134) with severe hemophilia A without inhibitors who were using FVIII prophylaxis received one 6 × 1013 vg/kg infusion of valoctocogene roxaparvovec. End points included annualized bleeding rate (ABR), FVIII infusion rate, FVIII activity, Haemophilia-Specific Quality of Life Questionnaire for Adults, adverse events, and immunosuppressant use. Results: Median follow-up was 261.1 weeks; 128 of 134 participants completed the study. For the 112 participants who enrolled from a previous noninterventional study (rollover population), mean ABR for treated bleeds declined by 83.3% (P < .0001), mean FVIII infusion rate declined by 94.9% (P < .0001), and mean ABR for all bleeds declined by 78.1% in the 5-year efficacy evaluation period vs baseline. In 132 modified intention-to-treat participants, mean and median FVIII activity at week 260 was 13.7 and 6.2 IU/dL, respectively (chromogenic assay). In year 5, 77.8% of rollover participants had 0 treated bleeds. One participant resumed prophylaxis since the 4-year data cutoff (25/134 across all follow-up). Haemophilia-Specific Quality of Life Questionnaire for Adults total score was improved from baseline at year 5. In year 5, alanine aminotransferase elevations occurred in 51 of 129 participants who entered year 5. Immunosuppressants were not used to manage them. No serious treatment-related adverse events occurred after year 1. Conclusion: Valoctocogene roxaparvovec provides durable hemostatic efficacy, FVIII activity, and improved health-related quality of life for ≥5 years, with no new safety signals.
SN - 2475-0379
SN - 2475-0379
ER -